Financial Performance - Q3 FY2025 - Consolidated net sales increased to $347.8 million, compared to $263.2 million in Q3 FY24[12] - Consolidated adjusted EBITDA increased to $45 million, an 85% increase compared to $29.7 million in Q3 FY24[12] - Animal Health sales increased by 42% to $258.4 million[10, 16] - Animal Health adjusted EBITDA increased by 73% to $63.1 million[10, 16] - Mineral Nutrition net sales increased by 4% to $66.8 million[10, 20] - Performance Products net sales increased by 28% to $22.7 million[10, 21] FY2025 Guidance - Net sales are projected to be between $1.260 billion and $1.290 billion[11] - Adjusted EBITDA is projected to be between $177 million and $183 million[11] - Adjusted EPS is projected to be between $1.96 and $2.09[11] Capitalization - Free cash flow was $49 million for the trailing twelve months[25] - The company has a gross leverage ratio of 3.0x, with $734 million in total debt[25] - The company has a net leverage ratio of 2.7x, with $664 million in net debt[25]

Core Insights - Phibro Animal Health (PAHC) reported a revenue of $347.8 million for the quarter ended March 2025, marking a year-over-year increase of 32.1% and an EPS of $0.63 compared to $0.31 a year ago [1] - The revenue fell short of the Zacks Consensus Estimate of $350.54 million by 0.78%, while the EPS exceeded the consensus estimate of $0.52 by 21.15% [1] Financial Performance - The company’s net sales by region showed varied performance: - United States: $209.94 million, a 31.8% increase year-over-year, but below the estimated $221.68 million [4] - Asia Pacific: $28.22 million, a significant 65.2% increase year-over-year, exceeding the estimate of $23.44 million [4] - Europe, Middle East and Africa: $38.91 million, a 17.3% increase year-over-year, below the estimate of $48.03 million [4] - Latin America and Canada: $70.75 million, a 31.9% increase year-over-year, surpassing the estimate of $55.39 million [4] Segment Performance - Animal Health segment reported net sales of $258.40 million, a 42.5% increase year-over-year, but below the estimate of $265.65 million [4] - Mineral Nutrition segment reported net sales of $66.80 million, a 4% increase year-over-year, slightly below the estimate of $66.88 million [4] - Animal Health Vaccines reported net sales of $33.40 million, a 1.5% increase year-over-year, below the estimate of $38.78 million [4] - Animal Health MFAs and other reported net sales of $181.60 million, a substantial 67.8% increase year-over-year, exceeding the estimate of $155.57 million [4] - Performance Products reported net sales of $22.70 million, a 28.5% increase year-over-year, surpassing the estimate of $18.01 million [4] EBITDA Performance - Adjusted EBITDA for the Animal Health segment was $63.10 million, above the average estimate of $60.59 million [4] - Adjusted EBITDA for the Corporate segment was -$17.30 million, better than the estimated -$19.57 million [4] Stock Performance - Phibro's shares have returned +6.5% over the past month, compared to the Zacks S&P 500 composite's +10.6% change, with a current Zacks Rank of 3 (Hold) indicating potential performance in line with the broader market [3]